Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer

10 Jan 2012

Abstract excerpt

PURPOSE: To examine gene expression differences between pre- and post-neoadjuvant systemic therapy (NST) specimens of breast cancers and identify biologic changers that may lead to new therapeutic insights. METHODS: Gene expression data from prechemotherapy fine needle aspiration specimens were compared with resected residual cancers in 21 patients after 4 to 6 months of NST. We removed stroma-associated genes to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Cancer Risks and Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22235097
DOI: 10.1158/1078-0432.ccr-11-2762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast CancerPMID 22235097Read ↗

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual DiseaseSemantic proximity Read ↗

Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancerSemantic proximity Read ↗

Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome.Semantic proximity Read ↗

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomasSemantic proximity Read ↗

Molecular characterization of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour responseSemantic proximity Read ↗

Adenosine triphosphate citrate lyase alters cellular myelocytomatosis oncogene signaling and fatty acid oxidation in residual breast cancer tumor tissues after neoadjuvant treatmentSemantic proximity Read ↗

Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to LetrozoleSemantic proximity Read ↗

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.Semantic proximity Read ↗

Biomarkers of residual disease after neoadjuvant therapy for breast cancer.Semantic proximity Read ↗

Gene expression signatures of morphologically normal breast tissue identify basal-like tumorsSemantic proximity Read ↗

Evaluation of drug resistance markers in breast cancers : roles in stemness and epithelial-to-mesenchymal transitionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.